Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 8 years
- Director since
- 2023
8 years of board service in total across 2 boards, counting each seat separately. Longest: Royalty Pharma plc, 3 years.
Royalty Pharma plc
Director
Regeneron Pharmaceuticals Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Royalty Pharma plc June 4, 202699.7%
-
Regeneron Pharmaceuticals Inc. June 13, 202582.5%
-
Royalty Pharma plc May 12, 202598.9%
-
Royalty Pharma plc June 6, 202498.9%
-
Royalty Pharma plc June 22, 202399.4%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 30, 2026 | Royalty Pharma plc | Grant or award | +689 | $54.40 | $37,482 |
| Jun 5, 2026 | Royalty Pharma plc | Grant or award | +4,545 | — | — |
| Mar 31, 2026 | Royalty Pharma plc | Grant or award | +815 | $45.98 | $37,474 |
| Jan 7, 2026 | Regeneron Pharmaceuticals Inc. | Option exercise | +1,500 | $374.12 | $561,180 |
| Jan 7, 2026 | Regeneron Pharmaceuticals Inc. | Open-market sale | −1,500 | $800.00 | $1,200,000 |
| Jan 2, 2026 | Regeneron Pharmaceuticals Inc. | Grant or award | +155 | — | — |
| Dec 31, 2025 | Royalty Pharma plc | Grant or award | +967 | $38.74 | $37,462 |
| Nov 20, 2025 | Regeneron Pharmaceuticals Inc. | Option exercise | +760 | $371.40 | $282,264 |
| Nov 20, 2025 | Regeneron Pharmaceuticals Inc. | Open-market sale | −760 | $750.00 | $570,000 |
| Sep 30, 2025 | Royalty Pharma plc | Grant or award | +1,047 | $35.79 | $37,472 |
| Jun 30, 2025 | Royalty Pharma plc | Grant or award | +1,064 | $35.24 | $37,495 |
| May 13, 2025 | Royalty Pharma plc | Grant or award | +7,614 | — | — |
| Mar 31, 2025 | Royalty Pharma plc | Grant or award | +1,141 | $32.87 | $37,505 |
| Jan 2, 2025 | Regeneron Pharmaceuticals Inc. | Grant or award | +166 | — | — |
| Dec 31, 2024 | Royalty Pharma plc | Grant or award | +1,503 | $24.94 | $37,485 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.